SLN124 is being developed for the treatment of iron overload disorders like ß -Thalassemia, Myelodysplastic syndrome (MDS) and Hereditary Hemochromatosis (HH). The investigational candidate was demonstrated to reduce
The post Silence seeks UK MHRA approval to launch first-in-human study of SLN124 appeared first on Pharmaceutical Business review.
Original Article: Silence seeks UK MHRA approval to launch first-in-human study of SLN124